TAVR for Today’s Patient: Updates on Data, Risk, Anatomy, and Access

LISTEN IN NOW as a general cardiologist, surgeon, and interventionalist delve into the latest evidence—including the Evolut™ TAVR 5-Year Low Risk data and SMART Trial 2-Year update—to guide appropriate treatment decisions for patients with severe symptomatic aortic stenosis. TAVR or SAVR? Gain actionable real world insights regarding therapy considerations and lifetime management strategies in the low risk and/or small annulus patient population.